GeneDx Slashes FY26 Revenue Outlook by Over 10% After Q1 Misses Estimates
Summary
GeneDx Holdings Corp. reported first-quarter revenue of $102.30 million and adjusted EPS of -$0.28, significantly missing analyst estimates of $112.96 million and -$0.01, respectively. More critically, the company dramatically lowered its full-year 2026 revenue guidance to $475 million-$490 million, a substantial reduction from its previous outlook of $540 million-$555 million. This news follows an 8-K filing earlier today reporting Q1 results, but this Reuters headline provides the crucial interpretation of missing estimates and the significant guidance reduction. The substantial cut in full-year guidance, representing over a 10% reduction at the midpoint, signals a material deterioration in the company's near-term financial prospects, despite a 34% year-over-year increase in test volumes. This development is highly negative and will likely trigger significant downward pressure on the stock, which is already trading near its 52-week low. Traders will be watching for analyst reactions and further commentary from management regarding the revised outlook.
At the time of this announcement, WGS was trading at $46.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $55.17 to $170.87. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.